Aminopterin/methotrexate embryofetopathy

disease
On this page

Also known as aminopterin embryopathy syndromeaminopterin fetopathy syndromeaminopterin syndromefetal aminopterin syndromefetal methotrexate syndromefoetal aminopterin syndromefoetal methotrexate syndrome

Summary

Aminopterin/methotrexate embryofetopathy (MONDO:0016004) is a disease. A subtype of toxic or drug-related embryofetopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 33

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families17WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Signs & symptoms

Clinical features (HPO)

33 HPO clinical features (Orphanet curated; top 33 by frequency):

HPO IDTermFrequency
HP:0000238HydrocephalusVery frequent (80-99%)
HP:0000286EpicanthusVery frequent (80-99%)
HP:0000303Mandibular prognathiaVery frequent (80-99%)
HP:0000316HypertelorismVery frequent (80-99%)
HP:0000431Wide nasal bridgeVery frequent (80-99%)
HP:0000520ProptosisVery frequent (80-99%)
HP:0002323AnencephalyVery frequent (80-99%)
HP:0002652Skeletal dysplasiaVery frequent (80-99%)
HP:0002983MicromeliaVery frequent (80-99%)
HP:0003027MesomeliaVery frequent (80-99%)
HP:0004322Short statureVery frequent (80-99%)
HP:0009891Underdeveloped supraorbital ridgesVery frequent (80-99%)
HP:0000175Cleft palateFrequent (30-79%)
HP:0000252MicrocephalyFrequent (30-79%)
HP:0000347MicrognathiaFrequent (30-79%)
HP:0001511Intrauterine growth retardationFrequent (30-79%)
HP:0001883TalipesFrequent (30-79%)
HP:0002084EncephaloceleFrequent (30-79%)
HP:0002435MeningoceleFrequent (30-79%)
HP:0100335Non-midline cleft of the upper lipFrequent (30-79%)
HP:0000358Posteriorly rotated earsFrequent (30-79%)
HP:0001231Abnormal fingernail morphologyOccasional (5-29%)
HP:0001360HoloprosencephalyOccasional (5-29%)
HP:0001629Ventricular septal defectOccasional (5-29%)
HP:0001636Tetralogy of FallotOccasional (5-29%)
HP:0001696Situs inversus totalisOccasional (5-29%)
HP:0001792Small nailOccasional (5-29%)
HP:0004935Pulmonary artery atresiaOccasional (5-29%)
HP:0006101Finger syndactylyOccasional (5-29%)
HP:0007360Aplasia/Hypoplasia of the cerebellumOccasional (5-29%)
HP:0007370Aplasia/Hypoplasia of the corpus callosumOccasional (5-29%)
HP:0009601Aplasia/Hypoplasia of the thumbOccasional (5-29%)
HP:0010301Spinal dysraphismOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical nameaminopterin/methotrexate embryofetopathy
Mondo IDMONDO:0016004
Orphanet1908
NCITC98928
SNOMED CT65986000
UMLSC0432367
MedGen98491
MedDRA10071183
Is cancer (heuristic)no

Also known as: aminopterin embryopathy syndrome · aminopterin fetopathy syndrome · aminopterin syndrome · fetal aminopterin syndrome · fetal methotrexate syndrome · foetal aminopterin syndrome · foetal methotrexate syndrome

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › disorder of development or morphogenesisdevelopmental defect during embryogenesis › toxic or drug-related embryofetopathy › aminopterin/methotrexate embryofetopathy

Related subtypes (21): fetal iodine syndrome, fetal valproate syndrome, indomethacin embryofetopathy, cocaine embryofetopathy, fetal hydantoin syndrome, fetal trimethadione syndrome, vitamin K-antagonist embryofetopathy, fetal alcohol syndrome, diethylstilbestrol syndrome, fetal methylmercury syndrome, fetal minoxidil syndrome, phenobarbital embryopathy, toluene embryopathy, methimazole embryofetopathy, isotretinoin syndrome, mycophenolate mofetil embryopathy, thalidomide embryopathy, fetal carbamazepine syndrome, acitretin/etretinate embryopathy, fetal phenothiazine syndrome, propylthiouracil embryofetopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.